Paricalcitol is FDA-approved for which of the following condition(s):
Paricalcitol: It is a synthetic calcitriol derivative Reduces serum PTH levels without producing hypercalcemia or altering serum phosphorus Administered orally or intravenously FDA-approved for treating secondary hyperparathyroidism in patients with CKD
Rickets
Osteomalacia
Primary hyperparathyroidism
Secondary hyperparathyroidism
Pituitary-Hypothalmic System and Thyroid